Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. - Wikidata - wikimedia - TriplyDB

Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.

Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.

http://www.wikidata.org/entity/Q34202226

about

Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime Hydrolysis of platelet-activating factor by human serum paraoxonase Lipid peroxidation generates biologically active phospholipids including oxidatively N-modified phospholipids Generation and biological activities of oxidized phospholipids The effect of oxidized phospholipids on phenotypic polarization and function of macrophages.Oxidized phospholipid species promote in vivo differential cx43 phosphorylation and vascular smooth muscle cell proliferation Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6.Import and fate of fluorescent analogs of oxidized phospholipids in vascular smooth muscle cells.Tangier disease: epidemiology, pathophysiology, and management.The role of phosphotriesterases in the detoxication of organophosphorus compounds.Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure.Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis.Paraoxonase genes and disease.Polyunsaturated phospholipids promote the oxidation and fragmentation of gamma-hydroxyalkenals: formation and reactions of oxidatively truncated ether phospholipids High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis.HDL inhibits the effects of oxidized phospholipids on endothelial cell gene expression via multiple mechanisms Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase.Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response Regulation of NF-κB signaling by oxidized glycerophospholipid and IL-1β induced miRs-21-3p and -27a-5p in human aortic endothelial cells STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.Role of monocytes in atherogenesis.Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis.Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils.Lipoproteins modulate expression of the macrophage scavenger receptor Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target.Cardiovascular disease and rheumatoid arthritis: an update.Determination of phospholipase activity of PAF acetylhydrolase Aldose reductase-catalyzed reduction of aldehyde phospholipids Antigen-induced generation of lyso-phospholipids in human airways.Emerging roles of the intestine in control of cholesterol metabolism.Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase A2 and carboxyl ester lipase lipases in atherosclerotic plaque formation.Oxidised phospholipid regulation of Toll-like receptor signalling.Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations.

P2860

Q24542068-2DDA33D6-C893-441E-92D5-0D8C6A142977 Q26747100-9544A488-6193-401D-9B38-92B7C1B54714 Q26991853-060B760D-1048-4743-B782-837520AA57EC Q26997377-A09A52E6-DAD3-4DE6-BEB4-27D1BE93DB66 Q28212769-6F09EDFD-DA96-4C43-A5E9-4374336C5FDC Q28347908-7A6118DF-502E-45DA-BE24-A863B32C0A18 Q28389004-742CEEBA-1399-42B6-A4D4-4C890565AEB5 Q28389691-90A6F860-AE73-427A-8551-5EC0B0C48542 Q30268532-6622F51D-FA23-4FE2-837B-FA0F81451915 Q30435253-470864FF-EACE-4FD3-8BB1-86A7C04AD607 Q31464758-599ACA05-E881-486C-9151-B7770FF73D6D Q33265039-393C6801-4D14-4F76-97EE-2CDE965AF034 Q33402921-52C10FC6-F53D-43EA-946C-830F2F2B98AD Q33538521-E8E19ABB-5453-4676-AF52-BA1DB0D4A5CC Q33664201-A9FC8330-A584-4E21-8213-B14E67B86581 Q33687843-A1C3F027-D681-4A9D-AEFE-3F3FA19064CD Q33708692-F835E4BA-D47F-43F5-B436-B9620F3DED4D Q33719295-767BE15C-CE5C-41EF-BACE-1B6AFF1DEDC7 Q33806840-3EA88656-E335-4B56-99AE-6FC06BF42D8B Q33945091-1740B867-32B7-4585-A3C3-79B1EA61BF5C Q34492025-4598FA33-7239-470A-A144-0F4B64DD2312 Q34730934-EC923D15-8EE5-44D6-904A-AE2272973CA9 Q34757449-01B83DF4-D5DB-4121-98C8-02CD0A531413 Q35217973-31F56F66-7DFD-46FB-B887-2DFC502BDE7E Q35541858-803C5D00-E670-4A1C-8BCE-79E874800280 Q35541874-88887818-02A1-4CD5-A8F6-8CB39421D303 Q35730371-CE671C57-5815-4500-BDD7-6E0092DBFF65 Q35765135-5D4B7995-1F62-4596-9685-B5015C80A7F3 Q35766281-D9DAF2EF-91B0-4B79-8976-A3A3496C329B Q35768215-E909293F-2652-4987-9FFF-DCA8202B21C6 Q35768830-66D77936-4828-4FF3-BC5E-F9D954F1029E Q36187055-56A7C0D8-16F2-460D-99FD-85436171BB73 Q36218375-625E4A0D-25E1-4749-B745-78C270747229 Q36240691-B3C7CA4F-B868-4308-957F-E70DBECB5796 Q36330024-104D3F36-1B72-48C1-89CA-5E6D18CA6DE5 Q36366671-E2F6348C-6DB6-4EBF-9FA4-412CA13113DD Q36638194-7CF8C60E-AAB8-41EA-A9F7-BA8661649F76 Q36686099-1571AB7F-F08A-4D06-BB0D-1C4D2DDA53C4 Q36722515-A2B58328-C806-405D-ACF9-CDAB4E878F17 Q36723319-D2A4F627-E0AF-4BDD-BD12-00C6BCE7C808

P2860

Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.

http://www.wikidata.org/entity/Q34202226

description

1995 nî lūn-bûn

@nan

1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Effect of platelet activating ...... dized low density lipoprotein.

@ast

Effect of platelet activating ...... dized low density lipoprotein.

@en

Effect of platelet activating ...... dized low density lipoprotein.

@nl

type

label

Effect of platelet activating ...... dized low density lipoprotein.

@ast

Effect of platelet activating ...... dized low density lipoprotein.

@en

Effect of platelet activating ...... dized low density lipoprotein.

@nl

prefLabel

Effect of platelet activating ...... dized low density lipoprotein.

@ast

Effect of platelet activating ...... dized low density lipoprotein.

@en

Effect of platelet activating ...... dized low density lipoprotein.

@nl

P1433

Q34202226-B963D182-4E0F-47E1-9FDB-8CBCBEE52F96

P1476

Q34202226-D72C1C06-EC43-422E-8D1A-D348E16D3881

P2093

Q34202226-047D66AB-C163-49DF-848D-0AF0489AB8A0

Q34202226-36B86556-27B8-4E55-9999-EBD33BB60E58

Q34202226-4307A840-D821-4903-BBD5-30B9D6E5FAAF

Q34202226-61043FED-29EE-463D-AC1A-5155B7CAAFFC

Q34202226-66EF751C-CCD3-43A4-9897-CB90F03C63D7

Q34202226-69322EBB-B772-4FBB-9CD8-27F735A783D6

Q34202226-70D2B331-E5B3-4F0F-9C4F-E8489FA3485D

Q34202226-874BE103-C5A5-4FD5-9E7A-CF4DFF902D6A

Q34202226-C4701636-F6EA-4D8F-BCC0-0444601F863F

Q34202226-FBA08C1A-B32E-40F8-A9A6-7043CF999A37

P2860

Q34202226-008FAC8B-C483-429D-9ED9-FF5FB9A0F2F3

Q34202226-0932A44D-04DB-4EF3-B96F-F83B9EED18DE

Q34202226-2F46A11A-958C-49EF-BABD-7610495CBB06

Q34202226-31467211-BA5B-4566-8A00-5EB2F0EEB2AF

Q34202226-3475AFFC-9A05-4D71-AE9E-3C18311BC2E4

Q34202226-38536C24-F78B-4A2F-AB6C-811335C561CB

Q34202226-385DC467-D192-4F20-874B-23770AD47D7A

Q34202226-39BFCDFD-07E9-46EB-ACF0-1C3271269F3C

Q34202226-40801CB4-E41C-48DD-A44D-12515F8D2BE3

Q34202226-4D855B8D-35E4-48EA-9750-E4E9D1523978

P304

Q34202226-A040DF86-43C9-40FF-86D8-CB0B9AA88404

P31

Q34202226-9D57B0C4-AD8C-4BA4-89C0-01139A57FEB9

P356

Q34202226-4C0A91C5-0CD6-411C-AE80-9D31BE639069

P407

Q34202226-524174FF-39AF-4B5F-8B02-546F90EA5FD8

P433

Q34202226-8F8DCD70-DB4C-47E6-AD22-4989BFF5BAF1

P478

Q34202226-052058EC-BDDF-4ED1-AE36-1296B405A3BA

P577

Q34202226-BE06DCE2-4F67-4084-8FC9-F5BDD08A8041

P5875

Q34202226-91D7C5F5-93CA-4E30-885B-80095758EE7A

P698

Q34202226-BA2575B2-D175-405E-AFE8-58B3E4C42135

P921

Q34202226-8417EF10-2FD7-45AF-B16A-3AE17F4B1BA0

P932

Q34202226-A8FAD9D3-6F71-4A72-BCD0-ED1E9882294A

P356

P1433

Journal of Clinical Investigation

P1476

Effect of platelet activating ...... dized low density lipoprotein.

@en

P2093

A D Watson

http://www.w3.org/2001/XMLSchema#string

A M Fogelman

http://www.w3.org/2001/XMLSchema#string

A Sevanian

http://www.w3.org/2001/XMLSchema#string

B N Du

http://www.w3.org/2001/XMLSchema#string

D M Stafforini

http://www.w3.org/2001/XMLSchema#string

J A Berliner

http://www.w3.org/2001/XMLSchema#string

M Navab

http://www.w3.org/2001/XMLSchema#string

S M Prescott

http://www.w3.org/2001/XMLSchema#string

S Y Hama

http://www.w3.org/2001/XMLSchema#string

T M McIntyre

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells.

Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.

Phospholipase A2 activity of low density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100.

Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).

Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate.

Rapid separation of lipid classes in high yield and purity using bonded phase columns.

P304

774-782

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI117726

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

1995-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15337988

http://www.w3.org/2001/XMLSchema#string

P698

7860760

http://www.w3.org/2001/XMLSchema#string

P921

P932

295551

http://www.w3.org/2001/XMLSchema#string